

28 November 2016

Dear Sirs / Madams:

Verastem, Inc., located at 117 Kendrick St., Needham, MA 02494, United States is purchasing the clinical development compound duvelisib (IPI-145-06) from Infinity Pharmaceuticals, Inc., located at 784 Memorial Drive, Cambridge, MA 02319, United States. With the purchase of the compound, Infinity is transferring sponsorship of the clinical study

IPI-145-19; "A Two-arm, Phase 1b/2 Study of IPI-145 Administered in Combination with Rituximab or Obinutuzumab in Subjects with Previously Untreated CD20+ Follicular Lymphoma (EudraCT Number 2014-005459-13)"

to Verastem, Inc.

The date at which this transfer is final is January 1, 2017.

Verastem, Inc. therefore, confirms all duties of the sponsor will transfer from Infinity to Verastem by this date, and that Verastem accepts all sponsor duties for the above-reference clinical study.

Sincerely,



Greg Berk, M.D.
Chief Medical Officer